Phase 3 Trial of mRNA Cancer Vaccine Reports 82.2% Two-Year Recurrence-Free Rate

A phase 3 trial of an mRNA cancer vaccine in 1137 patients reports a two-year recurrence-free rate of 82.2%. The paper has been accepted by the New England Journal of Medicine, with the data to be presented first in the presidential symposium at the ESMO annual meeting. The study focused on preventing recurrence after surgical tumor removal.